Market Research Logo

ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review

ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The company’s therapeutic candidates in clinical development are focused at treating motor disability as a result of stroke, critical limb ischaemia and the blindness-causing disease retinitis pigmentosa. Its lead CTX stem cell therapeutic candidate is a therapy for treating patients left disabled by a stroke. The company used its exclusive stem cell technologies for developing cell-based therapies for significant disease conditions where the cells can be administered “off-the-shelf” to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron is headquartered in Surrey, the UK.

ReNeuron Group Plc Key Recent Developments

Jul 19,2017: ReNeuron Group: Board change
Jun 29,2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017
May 11,2017: ReNeuron awarded major UK cell therapy manufacturing grant
Apr 21,2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes
Jan 23,2017: Merck Announces Emerging Biotech Grant Program Winners

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 6
ReNeuron Group Plc - Key Facts 6
ReNeuron Group Plc - Key Employees 7
ReNeuron Group Plc - Key Employee Biographies 8
ReNeuron Group Plc - Major Products and Services 9
ReNeuron Group Plc - History 10
ReNeuron Group Plc - Company Statement 11
ReNeuron Group Plc - Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 15
ReNeuron Group Plc - Business Description 15
ReNeuron Group Plc - Corporate Strategy 16
ReNeuron Group Plc - SWOT Analysis 17
SWOT Analysis - Overview 17
ReNeuron Group Plc - Strengths 17
ReNeuron Group Plc - Weaknesses 18
ReNeuron Group Plc - Opportunities 19
ReNeuron Group Plc - Threats 20
ReNeuron Group Plc - Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios - Capital Market Ratios 22
Financial Ratios - Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios - Interim Ratios 26
Financial Ratios - Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 29
ReNeuron Group Plc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Jul 19, 2017: ReNeuron Group: Board change 31
Jun 29, 2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017 32
May 11, 2017: ReNeuron awarded major UK cell therapy manufacturing grant 33
Apr 21, 2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes 34
Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 35
Dec 05, 2016: ReNeuron: Interim Results for the six months ended 30 September 2016 36
Sep 06, 2016: ReNeuron: AGM Trading Update 39
Jul 07, 2016: ReNeuron Group Reports Preliminary Results for the Year Ended 31 March 2016 40
Feb 23, 2016: ReNeuron relocates to South Wales 41
Feb 01, 2016: ReNeuron receives notice of grant of key US patent on its cell cryopreservation technology 42
Section 6 – Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Tables
ReNeuron Group Plc, Key Facts 6
ReNeuron Group Plc, Key Employees 7
ReNeuron Group Plc, Key Employee Biographies 8
ReNeuron Group Plc, Major Products and Services 9
ReNeuron Group Plc, History 10
ReNeuron Group Plc, Subsidiaries 14
ReNeuron Group Plc, Key Competitors 21
ReNeuron Group Plc, Ratios based on current share price 22
ReNeuron Group Plc, Annual Ratios 23
ReNeuron Group Plc, Annual Ratios (Cont...1) 24
ReNeuron Group Plc, Interim Ratios 26
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 29
ReNeuron Group Plc, Recent Deals Summary 30
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 46
Efficiency Ratios 46
List of Figures
ReNeuron Group Plc, Performance Chart (2013 - 2017) 25
ReNeuron Group Plc, Ratio Charts 27
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 28
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 29

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report